Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate ...

Indirect data suggest oral semaglutide outperforms orforglipron on weight loss and tolerability, with patients also favoring its treatment profile.

In part 3 of a 3-part interview, Susan Schniepp, Regulatory Compliance Associates Inc., makes a candid argument maintaining a ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

EMA states that reduction in animal testing will be gradual. The first qualification opinion for a NAM used in toxicity ...

EMA approved Johnson & Johnson’s daratumumab SC for self-administration, Europe’s first oncology injectable to offer this ...

Susan Schniepp, Regulatory Compliance Associates Inc., discusses siloed pharma data being a hidden risk, with AI as a ...

Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system ...

Lilly acquires Centessa for $6.3B, gaining an orexin receptor agonist pipeline targeting narcolepsy and other sleep-wake ...

New US pharmaceutical tariffs reach up to 100%, with exemptions for companies that strike pricing deals or commit to domestic manufacturing.

In this insightful interview, Richard Jaenisch, senior director of Education, Outreach, and Digital Experience at Open ...